Extension in Biological Technology

NeurogesX Reports Second Quarter 2009 Results

... of the PDUFA date can trigger a three-month extension to the original review timeline. On August 5, ... of Qutenza in Europe. In the U.S., the PDUFA date extension for Qutenza in PHN was not unexpected given the ... as a favorable result with only a three-month extension to our PDUFA date. With Astellas as our partner, ...

NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application

... with postherpetic neuralgia (PHN). The extension resulted from the Company's recent submission of ... of the PDUFA date can trigger a three-month extension to the original review timeline. Anthony ... and CEO, commented, "The FDA's three-month extension is not unexpected. We previously discussed the ...

SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia

... primary endpoint over one year of treatment in an extension study in patients with predominant, persistent ... About the study This study was a 26-week extension of a randomized, double-blind, multicentered, ... double-blind treatment regimen for the 26-week extension study. In ...

Blazing Trails: Dr. Ellery Knake Remembered for His Contributions to Weed Science

... Aaron Hager, associate professor and weed science extension specialist with the University of Illinois, ... Knake with its very first "Outstanding extension Award" and named him a Fellow for his ... Though Knake spent his career in academia and extension work, he paved the way for a new generation of ...

Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex

... the Exchange and the Company has been granted an extension until August 11, 2009 to regain compliance with ... to periodic review by Exchange staff during the extension period. Failure to make progress consistent with ... the continued listing standards by the end of the extension period could result in the Company being delisted ...

SENOMYX ANNOUNCES FIRST QUARTER 2009 FINANCIAL RESULTS

... in the coffee and coffee whitener fields - extension of discovery and development program with Ajinomoto Co., Inc. - extension of collaborative research and license agreement ... and no debt. "Senomyx started 2009 with the extension of our collaborative agreements with Ajinomoto ...

Novel Once Daily Anti-Epileptic Zebinix(R) Approved in the European Union

... the option of entering a one year open label extension study. ESL demonstrated significant and ... Acetate (ESL): Results of a One-Year Open-Label extension to Study BIA-2093-302. Poster presented at the ... Acetate (ESL): Results of a One-Year Open-Label extension to Study BIA-2093-303. Poster presented at the ...

Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting

... today positive results from its ongoing Phase 2 extension study of its investigational drug, Amigal(TM) ... 2009 Annual Meeting in Tampa, FL. Phase 2 extension Study Overview: Twenty-six subjects ... continue to receive treatment in an ongoing extension study designed to evaluate the long term safety ...

Weed Science Society of America Announces Winners in Annual Scientific Awards Program

... Fort Collins, Colorado - Outstanding extension Award for an individual exhibiting excellence in weed science extension outreach activities. Chris Boerboom, Ph.D. Professor and extension Weed Scientist University of Wisconsin-Madison ...

Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results

... 2 studies continue to be treated in a voluntary extension study to characterize the long-term safety and ... and dose regimens. Amicus expects data from this extension study to be available in the first quarter of ... an 11-week treatment period with an optional extension study. The objectives of the trial include the ...

NYSE Alternext US Accepts China Shenghuo's Compliance Plan for Continued Listing

... the Company's Plan and granted the Company an extension until November 19, 2008 to file the Form 10-Q and ... to periodic review by Exchange staff during the extension period. Failure to make progress consistent with ... the continued listing standards by the end of the extension period could result in the Company being delisted ...

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

... Phase 3 and Open Label extension Results Support Efficacy and Safety ... interim results of the uncontrolled open label extension (OLE) study were included as well. The data ... interim results from the ongoing Open Label extension (OLE) (GOUT 3) study for Puricase(R) ...

Cell Therapeutics to Request a Hearing With NASDAQ Following Receipt of Staff Determination Letter

... conclusion of the hearing process and during any extension period which may be granted by the Panel. It is ... and that the Panel has discretion to grant an extension not to exceed 180 days from the date of the Staff ... Listing Qualifications Panel or in obtaining any extension from such Panel, and that it may continue to ...

Evotec Extends Ongoing Collaboration With CHDI Worth up to US$ 37 Million

... Three-Year extension for Integrated Drug Discovery Support in the ... Disease drug discovery programs. This contract extension is worth up to US$ 37 million in research ... grown significantly. In addition to the contract extension announced today, the companies also have ...

Montana State University lab gives early warnings about biological invaders

... together for an interactive workshop using an MSU extension Web server. In a sense, the network has built ... or, potentially, human health. They also train extension agents, crop advisors and master gardeners to ... of the national system, when an ag producer, extension agent or consultant detects a suspicious pest in ...

GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases

... GlaxoSmithKline announced today results from the extension arm of a Phase II study on its first-in-class, ... and of the 51 patients enrolled in the extension arm with TYKERB plus capecitabine, eight remained ... Of the 51 patients enrolled in the extension arm, 10 (20 percent) who received TYKERB plus ...

Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics

... abdominal pain, fatigue, and diarrhea. Phase 3 extension 96-week study for Naglazyme (galsulfase) ... 27 at 8:15am -- Pivotal, Phase 3 open-label extension study reported safety and efficacy data of ... pivotal Phase 3 trial, followed by a 72-week extension study for a total of 96 weeks. -- Endpoints ...

Baxter and Novation Sign Multi-Year Contract Extension Valued at Over $200 Million for Medication Delivery Products

... extension Provides Members of University HealthSystem ... company, has signed a new two-year contract extension on behalf of UHC valued at over $200 million over the contract term. The extension will commence at the conclusion of UHC's previous ...

Coherent, Inc. Receives Expected Letter from NASDAQ

... on February 15, 2007 to request an extension for continued listing on the NASDAQ Global Select ... a decision granting the Company a conditional extension to file its Form 10-K for the fiscal year ended ... that the Listing Council will grant an extension for continued listing. Shares of Coherent common ...

TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimer's Disease

... Inc. (Nasdaq: TPTX ) today announced a one year extension of its research agreement with Eisai Co., Ltd. that was entered into on October 1, 2005. The extension marks the continuation of Eisai's support ... and Chief Executive Officer of TorreyPines. "The extension of our collaboration with Eisai not only ...

AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule

... Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. ... the ongoing Phase 3 study, until the end of 2011. Patients entering this extension study sponsored by the Company's partner sanofi-aventis, will be ...

Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA(TM) (Formerly LymphoStat-B(R)) in Patients With Active Systemic Lupus Erythematosus

... end of 52 weeks, 345 patients chose to participate in an optional 24-week extension phase of the study, during which all patients received belimumab. At Week ... clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550. HGS, Human Genome Sciences, ABthrax, Albuferon, BENLYSTA and ...

AEterna Zentaris Opens Extended Study for Cetrorelix in Benign Prostatic Hyperplasia

... the ongoing Phase 3 study, until the end of 2011. Patients entering this extension study will be followed-up for safety, International Prostate Symptom Score ... Patients in this randomized placebo-controlled study with open-label extension conducted under the supervision of lead investigator, Prof. Frans M.J. ...

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

... to the same period in the prior year is mainly attributable to a 12 month extension of the revenue recognition period for the initial payment from one of YM's ... same period in the prior year is mainly as a result of the above mentioned extension and the ending of monthly revenue recognition for one other deferred ...

Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes

... development. These analyses include data from patients in the ongoing extension of the DURATION-1 study who used exenatide once weekly produced at ... or not achieving the intended clinical endpoints; the DURATION-1 study extension results potentially not being accepted to support comparability; label ...

Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events

... (NDA) submitted to FDA. These analyses include data from the ongoing extension of the DURATION-1 study, and will be used to support comparability between ... or not achieving the intended clinical endpoints; the DURATION-1 study extension results potentially not being accepted to support comparability; ...

SENOMYX ANNOUNCES THE EXTENSION OF ITS COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT WITH AJINOMOTO CO., INC.

... the food, beverage, and ingredient supply industries, announced today the extension of one of its discovery and development programs with Ajinomoto Co., Inc., ... containing any flavor ingredients developed under the agreement. This extension does not impact the companies' activities with existing flavor ingredients ...

Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009

... the expiration of the subsequent offering period. During the extension of the subsequent offering period, BTB will accept for payment and ... shares into the offer. Procedures for tendering shares during this extension of the subsequent offering period shall be the same as during the ...

3SBio Inc. Announces Unaudited Fourth Quarter and Fiscal Year 2008 Results

... December 2008, the Company filed for approval of a TPIAO label extension for the treatment of idiopathic thrombocytopenic purpura (ITP) ... 36,000 IU dosage formulation of EPIAO, NuLeusin, and TPIAO label extension for the treatment of ITP. -- Initiate Ferumoxytol registration trial ...

Campbell Alliance Brand Management Practice to Present at EyeForPharma's Oncology Summit USA and Oncology Market Access Europe Conference

... Launch excellence Growth maximization Life cycle extension Capability enhancement About Campbell ... Campbell Alliance 919-844-7100, extension 7195 jforte@campbellalliance.com ...

Encorium Group Signs $3.1 Million of New Business Contracts Including an Extension of a Current U.S. Oncology Clinical Trial with a Major Pharmaceutical Company

... signing of $3.1 million of new business awards, primarily consisting of an extension of a current U.S. oncology clinical trial with a major global pharmaceutical company to be conducted in the U.S. and Europe. The extension increases the value of the contract from $12.4 million to $14.4 million. ...

Beyond Seizure Control in the Treatment of Epilepsy With New Anti-Epileptic Drug, Zebinix(TM)

... with Eslicarbazepine Acetate (ESL): Results of a One-Year Open-Label extension to Study BIA-2093-302. Poster presented at the American Epilepsy Society ... with Eslicarbazepine Acetate (ESL): Results of a One-Year Open-Label extension to Study BIA-2093-303. Poster presented at the American Epilepsy Society ...

Isis Reports Financial Results and Highlights for Third Quarter of 2008

... patients -- Provide an update on mipomersen from an ongoing open-label extension study in patients with FH -- Report Phase 2 study data in type 2 ... or fatty liver. Additionally, we will provide an update on our open-label extension study where we have patients who have been exposed to mipomersen from ...

deCODE genetics Announces Third Quarter 2008 Financial Results

... Market pending the conclusion of the hearing process and during any extension period which may be granted by the Panel. It is expected that the hearing would be held within 45 days. The Panel has discretion to grant an extension not to exceed 180 days from the date of the Staff notification for the ...

deCODE Requests Hearing With Nasdaq Following Receipt of Staff Determination Letter

... Global Market pending the conclusion of the hearing process and during any extension period which may be granted by the Panel. It is expected that the hearing would be held within 45 days. The Panel has discretion to grant an extension not to exceed 180 days from the date of the Staff notification for the ...

Memory Pharmaceuticals Provides Update on NASDAQ Listing Status

... equity in order to remain listed. The Company has requested an extension to December 3, 2008 to comply with this requirement and to achieve its ... However, there can be no assurance that the Company will be granted this extension by the Panel. The NASDAQ Capital Market is one of the three market tier ...

Osage Bio Energy Kicks Off 'Barley Bin Builder' Yield Contest

... looking forward to working with state grain organizations and land grant extension services in the Barley Bin Builder Yield Contest. Farmers in Delaware, ... in excess of 120 bushels per acre," said Wade Thomason, Virginia Tech extension Grain Specialist. "The Barley Bin Builder Yield Contest gives us a great ...

NicOx Reports Results for the First Three Quarters of 2008

... long term safety demonstrated for both doses of naproxcinod in the 301 extension study, with no unexpected safety findings. In addition, the patients' ... pressure, as well as by the good long term safety data observed in the 301 extension study. We have also significantly advanced our pre-launch activities ...

Galenea and Otsuka Pharmaceutical Extend & Expand Schizophrenia Research Collaboration

... -- Galenea Corp. and Otsuka Pharmaceutical Co., Ltd. announced today the extension and expansion of their research and development collaboration. The two ... nervous system (CNS) diseases. The new agreement calls for a one year extension of the initial five-year alliance and brings the total committed funding ...

BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC

... Product Line extension Builds on Existing Brand Strength and Pediatric ... our multivitamin granule product. Pediatric multivitamins is an ideal extension of our GoodBaby brand as it builds on our existing brand strength and ...